U.S. Equities: Upside Momentum Lost, But Not Breaking Down
In today's report we highlight key levels and several metrics we are watching that will provide us clues as to where the S&P 500 is headed...
434 Views
Personalis IPO: Personalising Cancer Trials and Treatments; Upside from Growth in Cancer Market
Personalis offers genomic sequencing to bio-pharmaceutical companies by fully analyzing sample tissue data of cancer patients. It provides its...
579 Views
Amarin--Our Talks With The CEO & An Update on New Trial Data Released at ACC Conference
Strong Q1 to Come: We recently had a call with Amarin's CEO, John Thero, and update our model with quarterly estimates. Q1 should see revenue...
2.6k Views
Amarin Q4 2018 Conference Call--Strong Sales & High Confidence
Q4 2018 Revenues Stronger Than Pre-Announcement on January 4th: Amarin released its Q4 2018 results today and held a conference call. Results of...
689 Views
Biosimilar Battlefield: The Remsima/Inflectra Warning
2019 marks an inflection point for Korean biosimilar companies Celltrion Healthcare (091990 KS), Celltrion Inc (068270 KS), and Samsung Biologics...
694 Views